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Introduction: Among the driver gene mutations in non–small-cell 
lung cancer, mutations in epidermal growth factor receptor (EGFR) are 
the most important because of their predictive role in selecting patients 
eligible for targeted therapy. Our aim was to study EGFR mutations in 
a Finnish non–small-cell lung cancer cohort of 528 patients.
Methods: Mutation testing was conducted on DNA extracted from 
paraffin-embedded, formalin-fixed tumor material using the follow-
ing real-time polymerase chain reaction-based kits: Therascreen 
EGFR PCR Kit and cobas EGFR Mutation Test.
Results: EGFR mutation frequency was 11.4% and all positive cases 
were adenocarcinomas, of which a majority had an acinar predominant 
pattern. Mutations were seen significantly more often in females and 
never-smokers than in males and smokers. The most frequent muta-
tions were L858R in exon 21 and deletions in exon 19. Overall survival 
of the patients, not treated with EGFR inhibitor, did not differ between 
EGFR mutation-positive and EGFR mutation-negative patients.
Conclusion: EGFR mutation profile in this Finnish non–small-cell 
lung cancer cohort resembles in many respect with that of other 
Western European cohorts, even though the overall frequency of 
mutations is slightly higher. We show the occurrence of EGFR muta-
tions in patients with occupational asbestos exposure and also in 
those diagnosed with chronic obstructive pulmonary disease who 
have not been often investigated before.
Key Words: EGFR, Mutations, Frequency, Lung adenocarcinoma, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 886–891)
Among the driver gene mutations in non–small-cell lung cancer (NSCLC), mutations in epidermal growth factor 
receptor (EGFR) are the most important because of their pre-
dictive role in selecting patients eligible for targeted therapy.1 
EGFR mutation frequency and histologic subtype distribu-
tion in Finnish NSCLC patients have not been studied ear-
lier. Because of the special heritage history of the Finnish 
population and the influence of ethnic background on the 
incidence of EGFR mutations, it is reasonable to study the 
Finnish population separately. The aim of our study was to 
examine EGFR mutation frequency in a cohort of 528 consec-
utive Finnish Caucasian NSCLC patients by using real-time 
polymerase chain reaction performed on DNA extracted from 
 formalin-fixed, paraffin-embedded tumor material.
MATERIALS AND METHODS
Patients
In total, we collected 613 formalin-fixed, 
 paraffin-embedded specimens, including 610 tumor and 3 
pleural effusion specimens, of NSCLC patients treated at the 
Hospital District of Helsinki and Uusimaa (HUS), Finland, 
during 2006 to 2012 (primary diagnosis for three patients in 
2004). Tumor and pleural effusion specimens were collected 
upon diagnosis or the surgical operation. In total, 528 speci-
mens were eligible to be tested for EGFR mutation status. 
Tumor cell content of the specimens ranged from 2 to 98%; in 
87% of the samples, tumor cell content was at least 20%. Of 
the patients with a test obtained, 53% were male, 77% had been 
diagnosed with adenocarcinoma (ADC), 12% with squamous 
cell carcinoma, 8% with large cell carcinoma, and 3% had 
other subtype or not otherwise specified type of NSCLC. The 
other subtype/not otherwise specified included 10 patients 
diagnosed with adenosquamous carcinoma, four patients 
with not otherwise specified NSCLC, and three patients 
with sarcomatoid carcinoma. Histologic diagnosis was based 
on pathologist’s evaluation according to the World Health 
Organization criteria. EGFR-positive cases were subtyped 
according to the updated International Association for the 
Study of Lung Cancer/American Thoracic Society/European 
Respiratory Society classification.2 Clinicopathologic char-
acteristics of the patients are presented in Table 1.
DNA Extraction and Mutation Detection
DNA from 496 formalin-fixed, paraffin-embedded tumor 
tissue specimens of NSCLC patients was extracted using 
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QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) as 
described earlier.3 Tumor DNA samples of 528 NSCLC patients 
were tested for EGFR mutations using the Therascreen EGFR 
PCR Kit (Qiagen, Manchester, United Kingdom) according to 
the manufacturer’s protocol, on the ABI7500 platform or the 
cobas EGFR Mutation Test (Roche Molecular Systems, South 
Branchburg, NJ; 28 patients) according to the manufacturer’s 
protocol, on the cobas z480 platform.
RESULTS
The total frequency of EGFR mutations was 11.4% 
(58 of 510). The mean age of patients with EGFR mutation 
was higher (69.2 ± 6.9 years) compared with patients with 
 wild-type EGFR (65.2 ± 8.8 years, p = 0.001). EGFR muta-
tions occurred more often in women (16.6%, 40 of 241) than 
in men (6.7%, 18 of 269, p < 0.001) and in never-smokers 
(32.8%, 22 of 67) than in ever-smokers (8.2%, 36 of 438, 
p < 0.001). A group of ever-smokers was divided into the 
following subgroups: light ex-smokers (smoking <20 years, 
cessation >10 years ago), medium ex-smokers (smoking >20 
years, ceased), and current smokers (current smokers, smok-
ing >20 years). Of the EGFR-mutated patients, 38% (22 of 
58) were never-smokers, 19% (11 of 58) light ex-smokers, 
24% (14 of 58) medium ex-smokers, and 19% (11 of 58) 
current smokers.
All mutations occurred in patients diagnosed with ADC. 
Vast majorities, 98%, of EGFR mutation-positive ADCs were 
invasive ADCs (53 of 54 with sufficient material for reliable 
reclassification) and one (2%) was diagnosed with nonmu-
cinous minimally invasive ADC. Of the 54  EGFR-positive 
ADCs, 40 (74%) were acinar predominant, of which 18 were 
of the mixed acinar type: 10 with papillary (one of these had 
also micropapillary pattern and one all four patterns), four 
with lepidic, three with solid pattern, and one with nonmu-
cinous minimally invasive ADC. The other EGFR-positive 
subtypes of invasive ADCs were lepidic (9%, five of 54), solid 
(7%, four of 54), micropapillary (4%, two of 54), and papil-
lary predominant (4%, two of 54).
The most frequent mutations were amino acid change 
L858R in exon 21 and deletions in exon 19, representing 
41.4% (24 of 58) and 36.2% (21 of 58) of all mutations, 
respectively. Other mutations consisted of G719X (8.6%, 
five of 58), L861Q (3.4%, two of 58), S768I (1.7%, one of 
58), and insertions in exon 20 (1.7%, one of 58), together 
representing 15.5% of all EGFR mutations. Also four dou-
ble EGFR mutants (6.9%) were detected: two patients with 
TABLE 1.  Clinicopathologic Characteristics of the Patients Studied
Total, N (%)* Tested, N (%)*
Result  
obtained, N (%)* EGFR wt, N (%)† EGFR+, N (%)† p Value
Total 613 528 510 452 58
Histology
  ADC 460 (75.0) 411 (77.8) 398 (78.0) 340 (85.4) 58 (14.6) < 0.001
  SCC 77 (12.6) 60 (11.4) 60 (11.8) 60 (100) 0
  LCC 43 (7.0) 40 (7.6) 38 (7.5) 38 (100) 0
  NSCLC NOS 33 (5.4) 17 (3.2) 14 (2.7) 14 (100) 0
Gender
  Male 339 (55.3) 279 (52.8) 269 (52.7) 251 (93.3) 18 (6.7) <0.001
  Female 274 (44.7) 249 (47.2) 241 (47.3) 201 (83.4) 40 (16.6)
Age, years
  Mean 65.9 65.7 65.7 65.2 69.2
  Range 26–90 26–90 26–90 26–90 55–85
Smoking
  Never 79 (12.9) 69 (13.1) 67 (13.1) 45 (67.2) 22 (32.8) <0.001
  Light 53 (86.5) 51 (9.7) 51 (10.0) 40 (78.4) 11 (21.6)
  Medium 211 (34.4) 178 (33.7) 173 (33.9) 159 (91.9) 14 (8.1)
  Current 264 (43.1) 225 (42.6) 214 (42.0) 203 (94.9) 11 (5.1)
  Data missing 6 5 5 5 0
Asbestos
  Exposed 57 (9.3) 48 (9.1) 46 (9.0) 41 (89.1) 5 (10.9) 0.498
  Non-exposed 261 (42.6) 226 (42.8) 219 (43.0) 198 (90.4) 21 (9.6)
  No sure information 295 (48.1) 254 (48.1) 245 (48.0) 213 (86.9) 32 (13.1)
COPD
  Yes 125 (20.4) 113 (21.4) 111 (21.8) 104 (93.7) 7 (6.3) 0.057
  No 488 (79.6) 415 (78.6) 399 (78.2) 348 (87.2) 51 (12.8)
*Proportions calculated from all patients in the group (column) in question.
†Proportions calculated from a total number of variable group (row) in question.
ADC, adenocarcinoma; COPD, chronic obstructive pulmonary disease; LCC, large cell carcinoma; NSCLC NOS, non-small-cell lung cancer.
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G719X and an insertion in exon 20, one patient with G719X 
and S768I, and one patient with L858R and S768I. Results 
are presented in Table 2.
EGFR mutations were found in 10.9% (five of 46, 
p = 0.498) of those patients who had been exposed to asbestos. 
These patients had a history of occupational exposure to asbes-
tos, but no diagnosis of pleural plaques or asbestosis or any 
other asbestos-related disease. In total, 6.3% (seven of 111) 
of those NSCLC patients diagnosed with chronic obstructive 
pulmonary disease (COPD) harbored EGFR mutation. EGFR 
mutations occurred less frequently, but not significantly so, in 
patients with COPD (p = 0.057).
There was no statistical difference in overall sur-
vival between ADC patients with wild-type EGFR and 
ADC patients with mutated EGFR (not treated with EGFR-
TKI; Fig. 1). Similarly, no statistical differences were 
seen in OS between EGFR mutation-positive and EGFR 
 mutation-negative patients when only ADC, nonsmoker 
patients were included in the analyses (Table 3). Overall 
survival data for patients tested for EGFR mutations and 
treated with EGFR TKIs (gefitinib or erlotinib) are presented 
in Supplementary Table 1 (Supplemental Digital Content, 
http://links.lww.com/JTO/A540).
DISCUSSION
In this study, EGFR mutations were detected in 11.4% 
of all NSCLC patients. The frequency is slightly higher than 
previously reported in Northern/Western Europeans.4–6 The 
small difference might be explained by the high propor-
tion of ADC patients in our cohort and the testing method 
used. As in many other previous studies, EGFR mutations 
detected in this study were limited to the ADC subtype. 
A majority, 74 %, of the tumors had predominant acinar 
subtype. Our findings are supported by a number of stud-
ies.7 In our study, EGFR mutations were most frequent in 
never-smokers, as expected. Notable is, however, that the 
frequency was very similar in all smokers regardless of 
current (heavy) or light smoking history. In contrast, oth-
ers have shown that EGFR mutations reduce in frequency 
with increasing cigarette consumption.8 Our results suggest 
that EGFR mutations also occur in heavy-smokers and that 
smoking status should not be considered as a strong indica-
tor for EGFR testing.
EGFR mutations type and their distribution were very 
similar to that reported previously.1 The most common muta-
tions were deletions in exon 19 and mutation L858R in exon 
21 which represented 77.6% (45 of 58) of all the mutations. In 
recent studies on European patients, the frequencies vary from 
72.2%6 to 85.1%.4
We found EGFR double mutations in 0.8% (four of 510) 
of the patients. Characteristics of the patients which harbored 
compound mutations are presented in Table 4. G719A + S768I 
and L858R + S768I have also been detected previously.9 The 
proportion of compound EGFR mutations has been quite low 
(Table 2), but frequencies of up to 9%10 have been found in 
studies on Asian NSCLC patients.
Of the patients whose occupational asbestos expo-
sure was established based on patient interviews, EGFR 
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mutation was found in 11% (five of 46). The patients with 
EGFR mutation and a history of asbestos exposure were 
diagnosed with ADC: three with acinar, one with lepidic, 
and one with solid predominant pattern. These patients were 
not diagnosed with asbestos-related diseases, that is asbes-
tosis or pleural plaques. All five patients were men and also 
had a history of smoking. Further large scale studies are 
needed to study an influence of asbestos exposure on EGFR 
mutations.
We found EGFR mutations in seven patients diagnosed 
with COPD. All of them were current smokers. Predominant 
growth patterns were acinar in five, lepidic in one, and solid in 
one case. However, mutations occurred more often in patients 
without COPD (Tables 1 and 2).
In this study, no difference in the survival rates 
between EGFR-negative and EGFR-positive patients was 
seen in patients not treated with EGFR TKIs. The prognos-
tic value of EGFR mutation status remains debatable: many 
studies have shown a difference in survival between EGFR 
 mutation-positive versus EGFR mutation-negative patients,11 
whereas many other studies have not seen a difference.12 
Similarly, a prognostic role for smoking history among EGFR 
mutants is somewhat contradictory, although in many of the 
studies never-smokers and/or light-smokers have been shown 
to have a better prognosis compared with ever-smokers and/
or heavy-smokers.11
In conclusion, EGFR mutation frequency observed in 
our Finnish NSCLC patient cohort is slightly higher than 
that reported in recent studies on patients of European ori-
gin. This may most likely be because of the relatively high 
proportion of ADC subtype in our patient cohort, although 
the type of mutation test used may also affect the results. 
Statistical significance was observed for differences in 
EGFR mutation occurrence in ADC subtype, women, and 
never-smokers compared with other subtypes, men, and 
smokers. Many of the mutations occurred in the acinar 
predominant pattern of ADC. Overall, our EGFR mutation 
testing results are concordant with the results reported from 
other European populations.
FIGURE 1.  Kaplan-Meier curve for all lung adenocarcinoma patients with known EGFR status and not treated with TK inhibi-
tors. Mean overall survival for wt EGFR patients was 68.6 ± 3.1 (95% confidence interval 62.6–74.7) and EGFR+ patients 
52.2 ± 6.1 (95% confidence interval 40.2–64.2) months, p = 0.460.
TABLE 3.  Overall Survival Estimates by Kaplan-Meier 
Analysis and p Value of Log Rank Test: No Statistical 
Difference Was Seen
Mean OS ± sem  
(95% confidence interval) p Value
ADC cases
EGFR+ 52.2 ± 6.1 (40.2–64.2) 0.460
EGFR− 68.6 ± 3.1 (62.6–74.7)
Never-smokers 53.3 ± 5.1 (43.3–63.2) 0.838
Ever-smokers 70.7 ± 3.2 (64.5–76.9)
EGFR+ cases
Never-smokers 52.2 ± 9.3 (34.0–70.4) 0.891
Ever-smokers 46.9 ± 6.1(34.9–58.9)
ADC, adenocarcinoma; OS, overall survival.
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TABLE 4.  Characteristics of the Non–Small-Cell Lung Cancer Patients with Compound EGFR Mutations
Mutation Gender Age
Predominant 
Subtype Survival (m)
Metastasis or 
Recurrence Smoking Status COPD
Asbestos 
Exposure
G719X, Ins 20 M 63 Acinar 13 Yes CS No Yes
G719X, S768I M 71 Solid 14 Yes MS No Yes
L858R, S768I M 79 Acinar + lepidic 26+ No NS No N/A
G719X, Ins 20 F 71 MIA 46+ No NS No N/A
COPD, chronic obstructive pulmonary disease; CS, current smoker; MIA, minimally invasive adenocarcinoma; MS, medium smoker; NS, never-smoker.
